Titre : Peptides natriurétiques

Peptides natriurétiques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C5
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Peptides natriurétiques : Questions médicales les plus fréquentes", "headline": "Peptides natriurétiques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Peptides natriurétiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-19", "dateModified": "2025-05-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Peptides natriurétiques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hormones peptidiques", "url": "https://questionsmedicales.fr/mesh/D036361", "about": { "@type": "MedicalCondition", "name": "Hormones peptidiques", "code": { "@type": "MedicalCode", "code": "D036361", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.644.548" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Facteur atrial natriurétique", "alternateName": "Atrial Natriuretic Factor", "url": "https://questionsmedicales.fr/mesh/D009320", "about": { "@type": "MedicalCondition", "name": "Facteur atrial natriurétique", "code": { "@type": "MedicalCode", "code": "D009320", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.644.548.585.500" } } }, { "@type": "MedicalWebPage", "name": "Peptide natriurétique de type C", "alternateName": "Natriuretic Peptide, C-Type", "url": "https://questionsmedicales.fr/mesh/D020098", "about": { "@type": "MedicalCondition", "name": "Peptide natriurétique de type C", "code": { "@type": "MedicalCode", "code": "D020098", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.644.548.585.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Peptides natriurétiques", "alternateName": "Natriuretic Peptides", "code": { "@type": "MedicalCode", "code": "D045265", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jens P Goetze", "url": "https://questionsmedicales.fr/author/Jens%20P%20Goetze", "affiliation": { "@type": "Organization", "name": "Department of Clinical Biochemistry, Rigshospitalet University Hospital, Copenhagen, Denmark." } }, { "@type": "Person", "name": "Speranza Rubattu", "url": "https://questionsmedicales.fr/author/Speranza%20Rubattu", "affiliation": { "@type": "Organization", "name": "Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. speranzadonatella.rubattu@uniroma1.it." } }, { "@type": "Person", "name": "John C Burnett", "url": "https://questionsmedicales.fr/author/John%20C%20Burnett", "affiliation": { "@type": "Organization", "name": "Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Department of Physiology and Bioengineering, College of Medicine Mayo Clinic, Rochester, MN, USA. Electronic address: burnett.john@mayo.edu." } }, { "@type": "Person", "name": "Naoto Minamino", "url": "https://questionsmedicales.fr/author/Naoto%20Minamino", "affiliation": { "@type": "Organization", "name": "Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Suita, Japan." } }, { "@type": "Person", "name": "Katherine N Bachmann", "url": "https://questionsmedicales.fr/author/Katherine%20N%20Bachmann", "affiliation": { "@type": "Organization", "name": "Vanderbilt Translational and Clinical Cardiovascular Research Center, University Medical Center, Nashville, TN (H.F.-T., J.F.F., K.N.B., D.K.G)." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37072660", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02510-4" } }, { "@type": "ScholarlyArticle", "name": "Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.", "datePublished": "2023-02-07", "url": "https://questionsmedicales.fr/article/36750531", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02438-9" } }, { "@type": "ScholarlyArticle", "name": "Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.", "datePublished": "2024-08-12", "url": "https://questionsmedicales.fr/article/39133885", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1212/NXI.0000000000200293" } }, { "@type": "ScholarlyArticle", "name": "COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY AFTER KIDNEY TRANSPLANT: SHOULD TREATMENT WITH C5 INHIBITOR BE LIFELONG?", "datePublished": "2024-04-14", "url": "https://questionsmedicales.fr/article/38615653", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000538826" } }, { "@type": "ScholarlyArticle", "name": "Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.", "datePublished": "2024-01-27", "url": "https://questionsmedicales.fr/article/38280096", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40620-023-01873-9" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Peptides", "item": "https://questionsmedicales.fr/mesh/D010455" }, { "@type": "ListItem", "position": 4, "name": "Hormones peptidiques", "item": "https://questionsmedicales.fr/mesh/D036361" }, { "@type": "ListItem", "position": 5, "name": "Peptides natriurétiques", "item": "https://questionsmedicales.fr/mesh/D045265" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Peptides natriurétiques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Peptides natriurétiques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Peptides natriurétiques", "description": "Comment diagnostiquer une insuffisance cardiaque ?\nQuels tests mesurent les peptides natriurétiques ?\nQuels symptômes indiquent un test de peptides natriurétiques ?\nQuelle est la valeur normale des peptides natriurétiques ?\nComment interpréter un taux élevé de BNP ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Peptides natriurétiques", "description": "Quels sont les symptômes des peptides natriurétiques élevés ?\nLes peptides natriurétiques causent-ils des symptômes ?\nComment les symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils différents chez les hommes et les femmes ?\nQuels signes cliniques sont associés aux peptides natriurétiques ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Peptides natriurétiques", "description": "Comment prévenir l'insuffisance cardiaque liée aux peptides natriurétiques ?\nL'alimentation influence-t-elle les niveaux de peptides natriurétiques ?\nL'exercice régulier aide-t-il à prévenir des niveaux élevés ?\nLe stress affecte-t-il les peptides natriurétiques ?\nLes contrôles médicaux réguliers sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Peptides natriurétiques", "description": "Quels traitements sont basés sur les peptides natriurétiques ?\nLes peptides natriurétiques sont-ils utilisés en thérapie ?\nComment les diurétiques agissent-ils sur les peptides natriurétiques ?\nLes traitements affectent-ils les niveaux de BNP ?\nQuels sont les effets secondaires des traitements ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Peptides natriurétiques", "description": "Quelles complications peuvent survenir avec des niveaux élevés de BNP ?\nLes peptides natriurétiques sont-ils liés à des maladies rénales ?\nComment les complications cardiovasculaires se manifestent-elles ?\nLes complications sont-elles réversibles ?\nQuels facteurs aggravent les complications liées aux peptides natriurétiques ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Peptides natriurétiques", "description": "Quels sont les principaux facteurs de risque d'insuffisance cardiaque ?\nLe tabagisme influence-t-il les niveaux de peptides natriurétiques ?\nL'âge est-il un facteur de risque ?\nLe stress chronique influence-t-il la santé cardiaque ?\nL'inactivité physique est-elle un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une insuffisance cardiaque ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic repose sur des examens cliniques, échographies et dosages de peptides natriurétiques." } }, { "@type": "Question", "name": "Quels tests mesurent les peptides natriurétiques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sanguins mesurent le BNP ou le NT-proBNP pour évaluer la fonction cardiaque." } }, { "@type": "Question", "name": "Quels symptômes indiquent un test de peptides natriurétiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Essoufflement, fatigue, œdème et palpitations peuvent justifier un test de peptides natriurétiques." } }, { "@type": "Question", "name": "Quelle est la valeur normale des peptides natriurétiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les valeurs normales varient, mais un BNP < 100 pg/ml est souvent considéré comme normal." } }, { "@type": "Question", "name": "Comment interpréter un taux élevé de BNP ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un taux élevé de BNP indique souvent une insuffisance cardiaque ou une surcharge volumique." } }, { "@type": "Question", "name": "Quels sont les symptômes des peptides natriurétiques élevés ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Essoufflement, fatigue, œdème et douleurs thoraciques peuvent être présents." } }, { "@type": "Question", "name": "Les peptides natriurétiques causent-ils des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont des biomarqueurs. Les symptômes proviennent de l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent être plus subtils chez les personnes âgées, rendant le diagnostic difficile." } }, { "@type": "Question", "name": "Les symptômes sont-ils différents chez les hommes et les femmes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes peuvent présenter des symptômes atypiques, rendant le diagnostic plus complexe." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés aux peptides natriurétiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent l'œdème périphérique, la tachycardie et l'hypertension." } }, { "@type": "Question", "name": "Comment prévenir l'insuffisance cardiaque liée aux peptides natriurétiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain, contrôler la pression artérielle et éviter le tabac." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les niveaux de peptides natriurétiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en sodium peut augmenter la pression artérielle et les peptides natriurétiques." } }, { "@type": "Question", "name": "L'exercice régulier aide-t-il à prévenir des niveaux élevés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier améliore la santé cardiaque et peut réduire les niveaux de peptides natriurétiques." } }, { "@type": "Question", "name": "Le stress affecte-t-il les peptides natriurétiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut aggraver les problèmes cardiaques et augmenter les niveaux de peptides natriurétiques." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes cardiaques." } }, { "@type": "Question", "name": "Quels traitements sont basés sur les peptides natriurétiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les diurétiques, les inhibiteurs de l'ACE et les bêtabloquants." } }, { "@type": "Question", "name": "Les peptides natriurétiques sont-ils utilisés en thérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des analogues de peptides natriurétiques sont utilisés pour traiter l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Comment les diurétiques agissent-ils sur les peptides natriurétiques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les diurétiques réduisent le volume sanguin, ce qui peut diminuer les niveaux de peptides natriurétiques." } }, { "@type": "Question", "name": "Les traitements affectent-ils les niveaux de BNP ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement efficace peut réduire les niveaux de BNP, indiquant une amélioration." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure hypotension, déséquilibres électrolytiques et fatigue." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des niveaux élevés de BNP ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent l'insuffisance cardiaque, l'arythmie et l'hypertension." } }, { "@type": "Question", "name": "Les peptides natriurétiques sont-ils liés à des maladies rénales ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés peuvent indiquer une insuffisance rénale associée à des problèmes cardiaques." } }, { "@type": "Question", "name": "Comment les complications cardiovasculaires se manifestent-elles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent se manifester par des douleurs thoraciques, des essoufflements et des syncopes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie." } }, { "@type": "Question", "name": "Quels facteurs aggravent les complications liées aux peptides natriurétiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension, le diabète et l'obésité aggravent les complications cardiaques et rénales." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'insuffisance cardiaque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'hypertension, le diabète, l'obésité et les antécédents familiaux." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il les niveaux de peptides natriurétiques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque de maladies cardiaques et peut affecter les niveaux de peptides." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'insuffisance cardiaque augmente avec l'âge en raison de divers facteurs physiologiques." } }, { "@type": "Question", "name": "Le stress chronique influence-t-il la santé cardiaque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à l'hypertension et à d'autres problèmes cardiaques." } }, { "@type": "Question", "name": "L'inactivité physique est-elle un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le manque d'exercice augmente le risque de maladies cardiovasculaires et d'insuffisance cardiaque." } } ] } ] }

Sources (1719 au total)

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.

Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach... The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re... Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence.... Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.

In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ... A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12... After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g... Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH.... ClinicalTrials.gov identifier, NCT04085601....

Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.

In myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD) and aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (AQP4+NMOSD), the autoantibodies are mainly composed of IgG1, and comp... CSF-C3a, CSF-C4a, CSF-C5a, and CSF-C5b-9 levels during the acute phase before treatment in patients with MOGAD (n = 12), AQP4+NMOSD (n = 11), multiple sclerosis (MS) (n = 5), and noninflammatory neuro... CSF-C3a and CSF-C5a levels were significantly higher in MOGAD (mean ± SD, 5,629 ± 1,079 pg/mL and 2,930 ± 435.8 pg/mL) and AQP4+NMOSD (6,017 ± 3,937 pg/mL and 2,544 ± 1,231 pg/mL) than in MS (1,507 ± ... The complement pathway is activated in both MOGAD and AQP4+NMOSD, but MAC formation is lower in MOGAD, particularly in those with mild attacks, than in AQP4+NMOSD. These findings may have pathogenetic...

Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.

Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizuma... To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormali... Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazar... Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed...

In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.

Several diseases caused by the dysregulation of complement activation can be treated with inhibitors of the complement components C5 and/or C3. However, complement is required for serum bactericidal a... Serum from adults was collected before and after vaccination with the meningococcal serogroup B vaccine 4CMenB and tested for meningococcal killing. Since the B capsular polysaccharide is structurally... While only a few pre-vaccination sera showed SBA against the tested B meningococcal isolates, 4CMenB vaccination induced potent complement-activating IgG titers against isolates expressing a matching ... Compared to the SBA triggered by A,C,W,Y capsule polysaccharide conjugate vaccination, SBA against B meningococci expressing a matching fHbp allele was remarkably resilient against the alternative pat...